LEGN
Legend Biotech

1,053
Mkt Cap
$3.22B
Volume
1.09M
52W High
$45.30
52W Low
$16.24
PE Ratio
-10.77
LEGN Fundamentals
Price
$17.41
Prev Close
$17.87
Open
$18.18
50D MA
$19.12
Beta
0.50
Avg. Volume
2.41M
EPS (Annual)
-$1.61
P/B
3.21
Rev/Employee
$355,731.44
$3,472.23
Loading...
Loading...
News
all
press releases
Legend Biotech (NASDAQ:LEGN) Downgraded to "Hold" Rating by Truist Financial
Truist Financial lowered Legend Biotech from a "strong-buy" rating to a "hold" rating in a report on Friday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Hudson Bay Capital Management LP Has $7.17 Million Stock Position in Legend Biotech Corporation Sponsored ADR $LEGN
Hudson Bay Capital Management LP raised its holdings in shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) by 42.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 220,000 shares of...
MarketBeat·2d ago
News Placeholder
Legend Biotech Q1 EPS Estimate Decreased by HC Wainwright
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) - Research analysts at HC Wainwright reduced their Q1 2026 EPS estimates for shares of Legend Biotech in a report issued on Monday, March 16th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($0.04) per sh...
MarketBeat·4d ago
News Placeholder
Q2 EPS Estimates for Legend Biotech Lowered by HC Wainwright
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) - Research analysts at HC Wainwright cut their Q2 2026 earnings per share (EPS) estimates for shares of Legend Biotech in a...
MarketBeat·5d ago
News Placeholder
Legend Biotech (NASDAQ:LEGN) Upgraded at Truist Financial
Truist Financial raised shares of Legend Biotech from a "hold" rating to a "strong-buy" rating in a research report on Tuesday...
MarketBeat·10d ago
News Placeholder
Capital International Investors Sells 140,873 Shares of Legend Biotech Corporation Sponsored ADR $LEGN
Capital International Investors decreased its stake in shares of Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Free Report) by 13.0% in the third quarter, according to the company in its...
MarketBeat·10d ago
News Placeholder
Legend Biotech (NASDAQ:LEGN) Price Target Cut to $49.00 by Analysts at Morgan Stanley
Morgan Stanley lowered their price objective on shares of Legend Biotech from $50.00 to $49.00 and set an "overweight" rating for the company in a research report on Wednesday...
MarketBeat·12d ago
News Placeholder
Royal Bank Of Canada Has Lowered Expectations for Legend Biotech (NASDAQ:LEGN) Stock Price
Royal Bank Of Canada cut their price target on shares of Legend Biotech from $66.00 to $62.00 and set an "outperform" rating for the company in a report on Wednesday...
MarketBeat·12d ago
News Placeholder
Legend Biotech Q4 Earnings Call Highlights
Legend Biotech (NASDAQ:LEGN) executives highlighted accelerating global demand for CARVYKTI, improving profitability metrics, and expanding manufacturing capacity during the company's fourth quarter...
MarketBeat·13d ago
News Placeholder
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Rating of "Moderate Buy" by Analysts
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the sixteen research firms that are presently covering the...
MarketBeat·13d ago
<
1
2
...
>

Latest LEGN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.